Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials

被引：4
|
作者：
Zhang, Xi [1 ]
Ran, Yu-ge [1 ]
Wang, Kun-jie [2 ]
机构：
[1] Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Peoples R China
[2] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 12期
关键词：
cancer; meta-analysis; mTOR inhibitors; pneumonitis; RENAL-CELL CARCINOMA; PHASE-III TRIAL; DRUG-RELATED PNEUMONITIS; MAMMALIAN TARGET; DOUBLE-BLIND; BREAST-CANCER; NONINFECTIOUS PNEUMONITIS; NEUROENDOCRINE TUMORS; INTERFERON-ALPHA; RAPAMYCIN MTOR;
D O I：
10.2217/fon-2016-0020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. Materials & methods: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. Results: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. Conclusion: mTORi significantly increase the risk of severe pneumonitis in cancer patients.
引用
收藏
页码：1529 / 1539
页数：11
相关论文
共 50 条
  • [41] Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials
    Bristow, Sarah M.
    Bolland, Mark J.
    MacLennan, Graeme S.
    Avenell, Alison
    Grey, Andrew
    Gamble, Greg D.
    Reid, Ian R.
    BRITISH JOURNAL OF NUTRITION, 2013, 110 (08) : 1384 - 1393
  • [42] Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    Abdel-Rahman, Omar
    Fouad, Mona
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 183 - 193
  • [43] Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Wang, Yi
    Du, Xianling
    Xin, Hongqiang
    Xu, Ruimin
    CURRENT CANCER DRUG TARGETS, 2024, 24 (09) : 941 - 951
  • [44] Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients
    Liu, Bo
    Ding, Fengxia
    Liu, Yang
    Xiong, Geng
    Lin, Tao
    He, Dawei
    Zhang, Yuanyuan
    Zhang, Deying
    Wei, Guanghui
    ONCOTARGET, 2016, 7 (41) : 67661 - 67673
  • [45] Increased risk of severe infections in non-small-cell lung cancer patients treated with pemetrexed: a meta-analysis of randomized controlled trials
    Tong, Song
    Fan, Kai
    Jiang, Ke
    Zhai, Wei
    Fang, Bin
    Wang, Si-Hua
    Wang, Jian-Jun
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (01) : 31 - 37
  • [46] Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients A meta-analysis of randomized clinical trials
    Wei, Wei
    Luo, Zhibin
    MEDICINE, 2017, 96 (48)
  • [47] Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab
    Zhu, Jianhong
    Wu, Junyan
    Li, Guocheng
    Li, Jianfang
    Lin, Yin
    He, Zhichao
    Su, Chen
    Zhao, Wenxia
    Wu, Qianqian
    Chen, Zepeng
    Qiu, Kaifeng
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 423 - 428
  • [48] Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials
    Zhu, Xiaoqiang
    Tian, Xianglong
    Yu, Chenyang
    Hong, Jie
    Fang, Jingyuan
    Chen, Haoyan
    MEDICINE, 2016, 95 (34)
  • [49] Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials
    Zhang, Wei
    Feng, Li-Jin
    Teng, Fei
    Li, Yan-Hong
    Zhang, Xi
    Ran, Yu-Ge
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (03) : 311 - 320
  • [50] Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
    Qi, Wei-Xiang
    Huang, Yu-Jing
    Yao, Yang
    Shen, Zan
    Min, Da-Liu
    PLOS ONE, 2013, 8 (06):
12345